FDA Updates Guidance on Hepatic Impairment PK Studies

Sponsors conducting pharmacokinetic studies in patients with hepatic impairment now have updated FDA guidance to navigate, with direct implications for study design, data analysis, and the downstream labeling decisions that follow. The Center for Drug Evaluation and Research issued the document under docket FDA-2026-D-8693, covering both small molecules and therapeutic biological products.

The guidance addresses how hepatic impairment affects drug PK and, where clinically warranted, pharmacodynamics. For regulatory affairs leads, the scope is notable: the document applies across the development continuum, meaning sponsors at IND stage and those approaching NDA or BLA submission will need to assess alignment with the updated recommendations before locking study protocols or finalising label language on dosing adjustments.

QA directors and clinical operations teams should note that the guidance sits within the broader framework of 21 CFR Part 312 and intersects with ICH E7 considerations for special populations. Study design choices made early, patient stratification by hepatic function severity, PK sampling schedules, and the decision to include or waive a full hepatic impairment study, carry direct consequences for what the prescribing information can ultimately state about dose modification.

Comments on the guidance may be submitted at any time via the FDA's online portal or by post to Dockets Management, FDA, 5630 Fishers Lane, Rm 1061, Rockville, MD 20852, referencing docket number FDA-2026-D-8693.

Sponsors with active hepatic impairment studies or pending labeling negotiations should benchmark current protocols against the new recommendations before the next scheduled regulatory interaction.

Source: FDA Center for Drug Evaluation and Research via FDA Guidance Documents RSS Feed, 2 September 2026.